Tonix Pharmaceuticals Holding (TNXP) Revenue (2022 - 2026)

Tonix Pharmaceuticals Holding has reported Revenue for 5 years, with the latest figure at $13.5 million in Q2 2026.

• On a quarterly basis, Revenue rose 577.88% year-over-year to $13.5 million in Q2 2026; TTM through Jun 2026 was $29.1 million, a 196.02% increase from a year earlier, with the FY2025 full-year figure at $13.1 million, up 29.85% from the prior year.
• Revenue was $13.5 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from $6.9 million in the prior quarter.
• The five-year high for Revenue was $13.5 million in Q2 2026, with the low at $2.0 million in Q2 2025.
• Average Revenue over 5 years is $4.2 million, with a median of $3.5 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Revenue plunged 37.7% in 2024, then jumped 577.88% in 2026.
• Over 5 years, Revenue stood at $3.6 million in 2022, then rose by 3.96% to $3.8 million in 2023, then slumped by 31.68% to $2.6 million in 2024, then jumped by 108.75% to $5.4 million in 2025, then soared by 151.28% to $13.5 million in 2026.
• The last three Revenue figures came in at $13.5 million (Q2 2026), $6.9 million (Q1 2026), and $5.4 million (Q4 2025), per Business Quant data.